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Objectives
To evaluate the effects of testosterone-replacement therapy
(TRT) on prostate health indicators in hypogonadal men,
including rates of prostate cancer diagnoses, changes in
prostate-specific antigen (PSA) levels and lower urinary tract
symptoms (LUTS) over time.
Patients and Methods
The Registry of Hypogonadism in Men (RHYME) is a multi-
national patient registry of treated and untreated, newly-
diagnosed hypogonadal men (n = 999). Follow-up
assessments were performed at 3–6, 12, 24, and 36 months.
Baseline and follow-up data collection included medical
history, physical examination, blood sampling, and patient
questionnaires. Prostate biopsies underwent blinded
independent adjudication for the presence and severity of
prostate cancer; PSA and testosterone levels were measured
via local and central laboratory assays; and LUTS severity was
assessed via the International Prostate Symptom Score (IPSS).
Incidence rates per 100 000 person-years were calculated.
Longitudinal mixed models were used to assess effects of
testosterone on PSA levels and IPSS.
Results
Of the 999 men with clinically diagnosed hypogonadism (HG),
750 (75%) initiated TRT, contributing 23 900 person-months
of exposure. The mean testosterone levels increased from 8.3
to 15.4 nmol/L in treated men, compared to only a slight
increase from 9.4 to 11.3 nmol/L in untreated men. In all, 55
biopsies were performed for suspected prostate cancer, and 12
non-cancer related biopsies were performed for other reasons.
Overall, the proportion of positive biopsies was nearly identical
in men on TRT (37.5%) compared to those not on TRT
(37.0%) over the course of the study. There were no
differences in PSA levels, total IPSS, or the IPSS obstructive
sub-scale score by TRT status. Lower IPSS irritative sub-scale
scores were reported in treated compared to untreated men.
Conclusions
Results support prostate safety of TRT in newly diagnosed
men with HG.
Keywords
testosterone, hypogonadism, disease registry, benign prostatic
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Introduction
Hypogonadism (HG) due to testicular or non-testicular
causes affects ~2.1% of men aged ≥40 years, increasing to
3.2% and 5.1% in men aged 60–69 and 70–79 years,
respectively [1,2]. Prevalence is 2–3 times higher in men with
type 2 diabetes or other components of the metabolic
syndrome [3,4]. The recommended treatment for
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biochemically confirmed HG is testosterone-replacement
therapy (TRT), which can be administered via multiple
injectable, implantable, topical or oral formulations [5–7]. In
addition to symptomatic improvements [8–10], possible
benefits for TRT include reduction in body mass index (BMI)
and waist size, improved glycaemic control and lipid profile,
in addition to improvements in body composition, bone
mineralisation, and other cardio-metabolic indices [11–14].
Prostate cancer growth and BPH progression have long been
seen as major risks associated with TRT, with current
guidelines contraindicating TRT in men with a history of
prostate cancer or advanced BPH [5–7]. In contrast, findings
from very recent studies raise serious doubts about the
pathological role of TRT in either prostate cancer or BPH.
Snyder et al. [15] recently reported results of a large, National
Institutes of Health-funded, randomised trial of topical
testosterone compared with placebo in 800 men aged
>65 years with symptomatic HG. No evidence of BPH
progression or increased prostate cancer incidence was seen
over 12 months of treatment. Similar findings were reported
in a pooled, 5-year analysis of three single-centre, longitudinal
patient registries [16]. Prostate cancer rates among men on
TRT in this pooled analysis were lower than previously
reported for European men in this age category [17].
Independent systematic reviews have similarly concluded that
affirmative evidence is lacking for either prostate cancer risk
[18] or BPH progression [19,20] in association with TRT. On
the other hand, design flaws, including lack of untreated
controls or independent adjudication of clinical outcomes,
inadequate sample sizes, and short duration of follow-up are
key weaknesses in previously published studies.
The Registry of Hypogonadism in Men (RHYME) is a large,
multi-national prospective registry of men with HG, which
was designed and powered specifically to assess prostate
cancer outcomes in men with HG receiving TRT compared
with untreated men with HG or general population estimates.
The primary aim was to examine prospectively the
association between TRT and prostate health outcomes,
including prostate cancer incidence and BPH progression in
hypogonadal men na€ıve to TRT who are diagnosed and
treated according to current standard-of-care guidelines.
Patients and Methods
Registry of Hypogonadism in Men is an observational, non-
interventional disease registry with longitudinal data
collection in a large sample of clinically diagnosed, well-
characterised men with HG. Eligibility criteria included men
aged ≥18 years with a diagnosis of HG, confirmed by
abnormal testosterone levels on at least two occasions.
Physicians were encouraged to apply guideline
recommendations of total serum testosterone of <12.1 nmol/
L; free testosterone of <243 pmol/L, and a report of
bothersome symptoms by the patient [6,7]. Men were
excluded if they had received prior TRT with any product or
a past history of breast or prostate cancer, high-grade
prostatic intraepithelial neoplasia, radical prostatectomy or
life-expectancy shorter than 24 months as judged by the
clinical site investigator. Men with major psychiatric
disorders, drug or alcohol abuse or gender dysphoria were
also excluded. All eligible men were enrolled consecutively, a
key element of the design for reducing selection bias.
Each patient enrolled was scheduled for at least four and up
to five assessments over a minimum of 2 years starting at
baseline and then the following 3–6, 12, 24 and 36 months.
Additional diagnostic tests or procedures, including prostate
biopsy or ultrasonography, were determined by the treating
physician in consultation with the patient. This clinical
decision-making paradigm was designed intentionally to
reflect clinical practice in order to increase generalisability of
RHYME findings, being consistent with the
non-interventional nature of a registry design. Further details
of the registry design and methods have been published
previously [21].
Patient enrolment was initiated in 2009 and completed in
2011. On 30 September 2013, the registry was closed to
patient follow-up. In all, 25 clinical sites in six European
countries (Germany, Italy, The Netherlands, Spain, Sweden,
and UK) participated in enrolment. Site investigators included
approximately equal number of urologists (13) and
endocrinologists or general physicians (12). All the men
provided written informed consent before enrolment. Registry
protocols were approved by local Ethics Committees at each
clinical site.
The primary endpoint for RHYME was the proportion of
positive prostate biopsies observed after 2 years. For our
primary statistical comparison, we assumed that the expected
positive biopsy rate under the null hypothesis of no effect of
TRT would be ~30%, based on prevalence rates for similar
aged men in large, community-based studies [17,22–24].
Secondary aims of the registry were to examine changes in
PSA, LUTS, and other health outcomes. Data were collected
through abstraction of medical records and a self-
administered questionnaire designed to obtain information on
demographic characteristics, lifestyle factors (e.g., smoking,
physical activity), and other health information (prostate-
related symptoms, health-related quality of life) using
standardised instruments, including the IPSS. Local laboratory
assays (testosterone, LH, PSA), were obtained by site
investigators and used for determining eligibility and
treatment response, while independent central laboratory
assays were obtained for blinded evaluation of treatment
outcomes.
All prostate-biopsy reports, prostatectomy findings and
relevant supporting documents were reviewed by an
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independent Clinical Endpoints Committee (CEC Members:
C. Roehrborn (Chair), F. Schr€oder, G. Cunningham, G.
Jackson) and used for research purposes only. The
adjudication process by the committee included blinded
review of clinical data and pathology reports. The committee
adjudicated de-identified biopsy reports and prostatectomy
findings as ‘positive’ or ‘negative’ for prostate cancer.
Adjudication included determination of the final Gleason
score and T-Stage classification, based on review of the
pathology findings. DRE and TRUS were performed only as
medically indicated. Reasons for biopsy requests were
recorded (e.g., PSA level rise, elevated PSA level, abnormal
DRE or TRUS findings) in addition to details of prostate
surgery or other treatments. Urogenital surgical procedures
and cancer-related outcomes were monitored at every study
visit.
Statistical Analyses
Men were considered ‘treated’ if they were on active TRT at
one or more visits during the study period. Conversely,
untreated subjects did not receive TRT at any time during the
period of monitoring. Descriptive statistics (i.e. means,
standard deviation [SD]) were used for assessing baseline
characteristics and testosterone use. Person-time of exposure
was calculated as the time up to prostate cancer diagnosis or
final contact. Prostate cancer incidence rates for treated and
untreated men were calculated as the number of events
divided by the total person-time, multiplying by 100 000.
Longitudinal mixed-model analyses evaluated changes in
outcome variables (i.e. PSA level, IPSS) by treatment, time,
and the interaction of time and treatment accounting for
repeated, correlated observations in the same patient. TRT
was treated as time-varying. PSA level and IPSS outcomes
were log-transformed and treated as time-varying. Using
baseline measured covariates, multivariate modelling was used
to control for potential confounders. All covariates were
entered into single multivariate models predicting each
outcome; those with a P ≤ 0.2 in each model were selected as
final covariates for the fully adjusted model.
Results
Of the 1 006 men enrolled, seven were ineligible, resulting in
an analytic cohort of 999 patients (Fig. 1). In all, 71 men
discontinued the study, resulting in a patient retention rate of
92.9% over 3 years of follow-up. Approximately 23 900
person-months were accrued, which represented 99.6% of the
targeted follow-up period.
The mean (SD) age was 59.1 (10.5) years; treated and
untreated men did not differ in age, type of HG (primary vs
secondary) or other sociodemographic characteristics
(Table 1). Men receiving TRT had a higher prevalence of HG
symptoms, erectile dysfunction, urological and psychiatric
conditions prior to enrolment than untreated men, although
medication use at baseline was similar across the two groups.
About 40% of both groups had moderate-to-severe LUTS
(IPSS > 8) at baseline. Prior negative biopsies were recorded
for 19 (2.5%) treated men and 18 (7.2%) untreated men and
a higher percentage of past abnormal DREs were reported for
untreated (38.2%) compared to treated (23.3%) men.
Testosterone Administration and Compliance with
Treatment
In all, 750 (75%) men received a prescription for TRT and
249 (25%) did not receive TRT in any form. Testosterone
prescriptions were mostly for topical gels (68%) or injectables
(31%), with only 2% receiving orally administered drugs.
Most of the treated men (70%) were consistent users (every
study visit after baseline) with a low treatment
discontinuation rate of only 17%. About 16% of men on TRT
received testosterone at only one visit. Most of the treated
men (75%) received testosterone at two or more consecutive
visits. Patterns were similar for topical and injectable
testosterone use. Most oral users (75%) used testosterone at
three consecutive visits.
As shown in Fig. 1, the mean (SD) total testosterone
concentration was 8.3 (3.9) nmol/L before TRT in the cohort
of treated men, which increased to 15.4 (10.4) nmol/L at
follow-up. In contrast, untreated men had a mean (SD)
baseline total testosterone concentration of 9.4 (3.7) nmol/L,
which increased to 11.3 (6.0) nmol/L at follow-up.
Primary Outcome: Positive Biopsy Rates and
Prostate Cancer Incidence
In all, 55 for cause prostate biopsies and 12 incidental
prostatectomies were performed on RHYME participants
during the period of follow up (Table 2). The most common
triggering events for biopsy referral were PSA level rise and/
or abnormally high PSA level, followed by an abnormal DRE
for both negatively and positively adjudicated biopsies. Most
biopsies were taken during the first 12 months following
enrolment. The positive biopsy rate was 37.5% in treated and
37.0% in untreated men. Oncological grading was performed
on 25 positive biopsies; Gleason scores of <7 were observed
in 14/18 (77.8%) positive biopsies in the treated group and 4/
7 in the untreated group. No prostate cancer-related deaths
were reported.
The overall prostate cancer incidence rate (1221.4 per
100 000 person-years) was comparable to the general
population (1251.9 per 100 000 person-years) (Table 3). The
incidence rate in men aged ≥60 years was 2030.1 per 100 000
person-years. The incidence rate in untreated men aged
≥60 years was higher compared to treated men (3941.6 vs
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1582.5 per 100 000 person-years, respectively), although not
statistically different (P = 0.07). The incidence rate ratio (RR)
in treated compared with untreated men (0.52, 95% CI 0.22,
1.26) showed no increased prostate cancer risk associated
with TRT.
Secondary Outcomes: Treatment Effects on PSA
Levels and IPSS
Baseline unadjusted PSA levels were slightly higher for
untreated than treated men, at a mean (SD) of 2.2 (9.1) ng/
mL vs 1.1 (1.7) ng/mL (Table 1). Changes in PSA levels over
time in both treatment groups are shown in Fig. 2. As shown,
adjusted PSA values increased slightly over the first
12 months of follow-up in men receiving TRT, but remained
stable at 24 months. Based on the longitudinal mixed-model
statistical analyses (Table 4), PSA levels were significantly
higher overall among men receiving TRT compared with
untreated men (P < 0.001); however, the interaction between
time and treatment was not significant.
Moderate-to-severe LUTS (IPSS ≥8) were reported at baseline
by 38.3% and 41.1% respectively of untreated and treated
men. As shown in Fig. 3, untreated men showed a slight
increase in adjusted total IPSS over time, although little
change was seen overall in either group (Fig. 3). Adjusted and
unadjusted longitudinal models showed modest, positive
effects of TRT on LUTS, with 7.1% lower total IPSS over
time (P = 0.004) and 7.9% lower irritative scores (P < 0.001)
in treated compared with untreated men, but no change in
IPSS obstructive scores (P = 0.33; Table 4).
Discussion
In this large, multi-national registry of men with HG, we
found no evidence of increased rates of prostate cancer
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Fig. 1 Patient disposition and testosterone-replacement therapy (TRT) patterns of use.
© 2016 The Authors
BJU International © 2016 BJU International 219
Testosterone and prostate cancer
diagnoses in men receiving TRT compared to untreated men
in the registry. Based on blinded, independent adjudication of
67 prostate biopsies over 23 900 person-months of follow-up,
we observed almost identical unadjusted rates of positive
biopsies; 37.5% in men receiving TRT, compared with 37.0%
in untreated men. As the denominator (i.e., person-months of
observation) is higher in men receiving TRT compared with
untreated men, an overall trend towards a lower adjusted
incidence rate of positive biopsies was seen among men
receiving TRT compared with untreated men (adjusted RR
0.52, 95% CI 0.22, 1.26). There were no differences in
prostate cancer grade or severity in men on TRT compared
with untreated men or prostate cancer rates in the general
population. Abnormal DRE rates and referrals for other
urological procedures were similar in both groups, although a
trend was seen towards decreased irritative scores and total
IPSS in men receiving TRT compared with untreated men.
Overall, we found no evidence of increased risk of BPH
progression or prostate cancer incidence or severity in men
receiving TRT in RHYME. Minor differences were noted in
PSA levels and IPSS in treated and untreated men, which are
not likely of clinical significance.
Similarly, TRT administration did not result in an increase in
prostate cancer or LUTS/BPH in a pooled analysis of three
single-centre, longitudinal patient registries [16]. Moreover,
Table 1 Cohort baseline characteristics according to subsequent testosterone-replacement therapy (TRT) status.
Baseline characteristic N* Overall cohort TRT status
Untreated (n = 249) Treated (n = 750) P
n (%) or mean  SD n (%) or mean  SD n (%) or mean  SD
Age, years 999 59.1  10.5 59.7  11.1 58.9  10.3 0.30
Age group 999 0.27
<60 years 516 (51.7) 121 (48.6) 395 (52.7)
≥60 years 483 (48.4) 128 (51.4) 355 (47.3)
Type of HG 751 0.26
Primary HG (LH ≥7.6 IU/L) 135 (18.0) 39 (20.7) 96 (17.1)
Secondary HG (LH <7.6 IU/L) 616 (82.0) 149 (79.3) 467 (83.0)
BMI 989 30.0  5.5 29.4  5.1 30.2  5.7 0.04
Past surgeries/therapy 999
Orchidectomy 27 (2.7) 1 (0.4) 26 (3.5) 0.01
Orchidopexy 18 (1.8) 4 (1.6) 14 (1.9) 0.76
Pituitary surgery 28 (2.8) 5 (2.0) 23 (3.1) 0.36
Radiotherapy 17 (1.7) 3 (1.2) 14 (1.9) 0.46
HG symptoms at time of diagnosis 999
Erectile dysfunction 622 (62.3) 140 (56.2) 482 (64.4) 0.02
Decreased desire for sex 116 (11.6) 26 (10.4) 90 (12.0) 0.49
Fatigue/weakness 100 (10.0) 36 (14.5) 64 (8.5) 0.01
Infertility 39 (3.9) 18 (7.2) 21 (2.8) <0.01
Gynecomastia 979 98 (10.0) 17 (6.9) 81 (11.1) 0.06
Baseline comorbidities 999
Urological disease† 742 (74.3) 169 (67.9) 573 (76.4) 0.01
Endocrine disease‡ 532 (53.3) 129 (51.8) 403 (53.7) 0.60
Cardiovascular disorder 515 (51.6) 125 (50.2) 390 (52.1) 0.60
Pulmonary disease 130 (13.0) 29 (11.6) NA –
Psychiatric disease 151 (15.1) 24 (9.6) 127 (16.9) 0.01
Concomitant medications 999
Anti-hypertensive medications 495 (49.5) 119 (47.8) 376 (50.1) 0.53
Lipid lowering medications 391 (39.1) 89 (35.7) 302 (40.3) 0.20
Anti-diabetes medications 257 (25.7) 65 (26.1) 192 (25.6) 0.88
Erectile dysfunction medications 253 (25.3) 60 (24.1) 193 (25.7) 0.62
Peptic ulcer medications 180 (18.0) 41 (16.5) 139 (18.5) 0.48
LUTS severity (total IPSS) 980 0.87
None to mild (<8) 584 (59.6) 148 (61.7) 436 (58.9)
Moderate (8–19) 308 (31.4) 73 (30.4) 235 (31.8)
Severe (≥20) 88 (9.0) 19 (7.9) 69 (9.3)
Erectile dysfunction (IIEF score) 981 <0.01
None to mild (≥22) 343 (35.0) 104 (43.5) 239 (32.2)
Moderate to severe (<22) 638 (65.0) 135 (56.5) 503 (67.8)
Past prostate biopsies 999 37 (3.7) 18 (7.2) 19 (2.5) <0.001
Past DRE 999 774 (77.5) 181 (73.0) 593 (79.1) 0.05
Abnormal result 774 195 (25.2) 57 (31.5) 138 (23.3) 0.03
Male kin with prostate cancer 987 56 (5.7) 18 (7.3) 38 (5.1) 0.19
IIEF, International Index of Erectile Function. *Numbers vary for variables with missing data or indeterminate laboratory findings. †Urological disease included ejaculatory disorder,
erectile dysfunction, Peyronie’s disease, BPH, prostatitis and testicular cancer. ‡Endocrine disease included diabetes, dyslipidaemia, thyroid or parathyroid disorder, adrenal disorder,
pituitary disorder, and multiple endocrine neoplasia.
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recent unpublished 8-year follow-up data from this ongoing
study shows a higher rate of incident prostate cancer and
more aggressive tumours among untreated men compared
with those on TRT [25]. Other registry studies have observed
similar findings for long-term TRT effects on PSA and LUTS
[26–30]. In one large observational study [27], 1140 men
received testosterone undecanoate injections during an
observation period of 9–12 months. The mean (SD) PSA
levels increased slightly from 1.1 (0.9) ng/mL at baseline to
1.3 (1.2) ng/mL at 24 weeks, and then remained stable [27].
The Testim Registry in the United States (TRiUS) Registry
observed similar slight increases in PSA levels [29]. Other
studies have reported mild improvements in voiding
symptoms or LUTS following TRT [19,26,30]. A recent
systematic review noted that evidence is lacking of consistent
effects of TRT on LUTS [20], although there are indications
in some studies, including RHYME, of modest improvements
in men with LUTS who receive TRT [26,29].
This lack of an association between serum testosterone and
prostate cancer risk has similarly been confirmed in the
placebo arms of both the REduction by DUtasteride of
prostate Cancer Events (REDUCE) [31] and Prostate Cancer
Prevention Trial (PCPT) trials [32]. In reviewing these
findings, a new hypothesis has been advanced that the
magnitude of age-related declines in testosterone, rather than
a static level of testosterone measured at a single time-point
may trigger or promote the development of prostate cancer
[33]. Other studies have similarly reported higher rates of
high-grade prostate cancer in men with sub-normal
testosterone levels [34–36].
While the traditional view of endogenous or exogenous
testosterone as a potential trigger or ‘biological fuel’ for
prostate enlargement or cancer growth has been sharply
contested in recent years [37], concerns remain among
physicians and the public about prostate safety of TRT [38–
40]. Controlled trials of TRT have been under-powered or
too short in duration to adequately assess safety risks [15].
Moreover, patient selection factors and clinical trial
constraints can limit generalisability of trial results. Systematic
reviews and meta-analyses have also failed to provide
definitive outcome data regarding the potential risk of
prostate cancer or other adverse outcomes [8,18–20]. In
contrast, a well-designed patient registry offers advantages for
assessing both clinical benefits and long-term safety outcomes
in a more naturalistic, ‘real-world’ setting [41].
Major strengths of the present study include consecutive
enrolment of a large, multi-centre cohort of treated and
untreated men with HG with similar demographic and health
characteristics, power analyses to determine necessary sample
size for the study, inclusion of standardised central laboratory
measures of testosterone and PSA, and blinded adjudication
of all mortalities and prostate biopsy findings by an
Table 2 Biopsy findings according to testosterone-replacement therapy










Treated 30 (71.4) 18 (72.0) 0.96
Untreated 12 (28.6) 7 (28.0)
Study visit closest to prostate
biopsy, months
0.32
Baseline 2 (4.8) 1 (4.0)
3–6 6 (14.3) 9 (36.0)
12 18 (42.9) 8 (32.0)
24 9 (24.3) 5 (20.0)
36 7 (16.7) 2 (8.0)
Reason(s) for prostate biopsy*
PSA level rise 18 (54.6) 15 (68.2) 0.28
Abnormally high PSA level 26 (78.8) 15 (68.2) 0.34
Abnormal TRUS 3 (9.1) 1 (4.6) 0.50
Abnormal DRE 12 (36.4) 9 (40.9) 0.72
Other 0 (0.0) 0 (0.0) –
Procedure type 0.21
TRUS-guided biopsy 21 (50.0) 16 (64.0)
Transperineal ultrasound
guided biopsy
14 (33.3) 4 (16.0)
Other biopsy procedure 0 (0.0) 1 (4.0)
Total (radical) prostatectomy 0 (0.0) 1 (4.0)
Partial prostatectomy 7 (16.7) 3 (12.0)
PSA level at time of
biopsy (n = 47)
Mean (SD), ng/mL 4.0 (3.8) 11.1 (30.4) 0.20
Median (interquartile range), ng/mL 3.2 (1.7, 4.0) 3.2 (1.8, 5.8) –
PSA level ≥3.0 ng/mL 0.93
Yes 17 (54.8) 9 (56.3)
No 14 (45.2) 7 (43.8)
*Multiple indicators were recorded as necessary.
Table 3 Prostate cancer (positive biopsy) incidence rates by testosterone-








Overall events, n 25 7 18 –




1221.4 2009.2 1059.8 0.17
Aged <60 years
population
Overall events, n 6 0 6 –




540.1 0 638.2 NR*
Aged ≥60 years
population
Overall events, n 19 7 12 –




2030.1 3941.6 1582.5 0.07
*NR, not reportable; no comparison of rates can be made for this age group, as there
were no cases reported in the <60-years age group of untreated men.
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independent committee of experts. Multiple modes of TRT
administration were permitted in RHYME, which increases
variability in the data, but contributes positively to the clinical
meaningfulness and generalisability of our present findings.
Finally, we achieved high rates of retention and treatment
compliance in the registry, which adds further to the validity
of our findings.
Study limitations should also be noted. An important
limitation is the absence of standard urodynamic measures of
prostate function or volume. Given the observational design
of the registry, these measures were only performed at the
discretion of the treating physician and were not routinely
included. Additionally, dihydrotestosterone levels and more
distal testosterone metabolites were not assessed in RHYME.
Men with a prior history of TRT or prostate cancer were
excluded by design and further studies of TRT in these
patients are needed. Although men receiving TRT were
similar in age, demographic and health characteristics to
untreated men in our cohort prior to treatment, we cannot
exclude potential confounding due to selection biases or other
unmeasured variables. On the other hand, the wide age range,
and presence of multiple comorbidities in our cohort support
the clinical relevance and generalisability of our present
findings.
Conclusion
In the present longitudinal disease registry of 999 men with
HG in six European countries, no evidence was seen of
increased prostate cancer rates or LUTS/BPH progression in
men receiving TRT compared with those who were untreated.
Prostate cancer incidence rates in RHYME were similar to
rates reported in large population studies and with findings
from other single country or single product registries. The
PSA level was minimally affected and slight improvements in
voiding symptoms were seen in our present study in men on
1.2




























1PSA values from central laboratory not available after 24 months.
3-6 Months 12 Months 24 Months
Fig. 2 Prostate-specific antigen (PSA) level changes over time in
testosterone-replacement therapy (TRT) treated and untreated men.
Table 4 Changes in prostate-specific antigen (PSA) level and International Prostate Symptom Score (IPSS): longitudinal modelling of treatment and time
effects.
Unadjusted Age-adjusted Fully adjusted
% Change per unit
(95% CI)
P % Change per unit (95% CI) P % Change per
unit (95% CI)
P
Central laboratory PSA level, ng/mL (n = 752)*,†
Treatment status 21.4 (13.8, 29.4) <0.001 21.5 (14.0, 29.6) <0.001 20.3 (12.1, 29.2) <0.001
Time (per month follow-up) 0.0 (–0.5, 0.6) 0.33 0.0 (–0.6, 0.6) 0.36 –0.0 (–0.6, 0.6) 0.47
Treatment status 9 time 0.3 (–0.4, 0.9) 0.46 0.3 (–0.4, 1.0) 0.39 0.3 (–0.4, 1.1) 0.38
IPSS (n = 896)‡
Treatment status –6.0 (–10.6,–1.2) 0.01 –6.0 (–10.5, –1.1) 0.02 –7.1 (–11.6, –2.3) 0.004
Time (per month follow-up) 0.0 (–0.4,0.4) 0.23 0.0 (–0.4, 0.4) 0.23 0.1 (–0.2, 0.5) 0.09
Treatment status 9 time 0.2 (–0.2,0.6) 0.33 0.2 (–0.2, 0.7) 0.26 0.1 (–0.3, 0.5) 0.62
IPSS obstructive sub-score (n = 913)§
Treatment status –3.1 (–8.0, 2.1) 0.23 –3.1 (–8.0, 2.1) 0.24 –3.0 (–8.8, 3.1) 0.33
Time (per month follow-up) 0.4 (0.0, 0.8) <0.001 0.4 (–0.0, 0.8) <0.001 0.5 (0.1, 0.9) <0.001
Treatment status 9 time –0.1 (–0.5, 0.4) 0.82 –0.0 (–0.5, 0.4) 0.90 –0.1 (–0.6, 0.4) 0.61
IPSS irritative sub-score (n = 910)¶
Treatment status –7.0 (–10.9, –3.0) <0.001 –6.9 (–10.8, –2.9) <0.001 –7.9 (–11.7, –3.9) <0.001
Time (per month follow-up) –0.2 (–0.5, 0.1) 0.60 –0.2 (–0.5, 0.1) 0.59 –0.1 (–0.4, 0.2) 0.98
Treatment status 9 time 0.3 (–0.1, 0.6) 0.11 0.3 (–0.0, 0.7) 0.08 0.2 (–0.1, 0.6) 0.21
*Numbers vary for variables with missing data or indeterminate laboratory findings. †Model covariates: Age at consent, Country, Modified Charlson Comorbidity Index, Central
laboratory LH ≥7.6 IU/L, Self-reported health, Central laboratory blood draw time (am), Physician-reported urological disorder, a-blockers, Other BPH medications, BMI. ‡Age at
consent, Country, Self-reported health, Physician-reported urological disorder, Physician-reported depression/anxiety/other psychiatric disorder, 5a-reductase inhibitors, a-blockers,
Other BPH medications, Anti-hypertensive medications, Lipid lowering medications. §Age at consent, Country, Central laboratory LH ≥7.6 IU/L, Site specialty, Self-reported health,
Physician-reported urological disorder, Physician-reported depression/anxiety/other psychiatric disorder, 5a-reductase inhibitors, Thiazide diuretics, a-blockers, Other BPH
medications. –Age at consent, Country, Months from HG diagnosis to consent, Self-reported daily hard physical work, Self-reported health, Physician-reported urological disorder,
Physician-reported depression/anxiety/other psychiatric disorder, a-blockers, Anti-hypertensive medications, Lipid lowering medications.
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TRT. These findings warrant confirmation in further long-
term, registries or randomised trials.
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